Journal Article

Cost avoidance using linezolid for methicillin-resistant <i>Staphylococcus aureus</i> infections in a specialist diabetes foot clinic

Matthew J. Young, Gemma Hodges and Joanne E. McCardle

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 67, issue 12, pages 2974-2975
Published in print December 2012 | ISSN: 0305-7453
Published online August 2012 | e-ISSN: 1460-2091 | DOI:
Cost avoidance using linezolid for methicillin-resistant Staphylococcus aureus infections in a specialist diabetes foot clinic

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care


Show Summary Details



An audit was performed to determine whether linezolid (Zyvox, Pharmacia Limited, Sandwich, UK) was being used in accordance with local guidelines and if this had an effect on admissions for diabetes foot ulceration.


Seven hundred and four patient records from 2005 to 2010 in the Diabetes Foot Clinic, Royal Infirmary of Edinburgh were audited for methicillin-resistant Staphylococcus aureus (MRSA) infections, admissions and antibiotic use.


Seventeen percent (n = 119) of patients had proven MRSA infections. Of these, 28% (n = 33) were prescribed linezolid, 94% (n = 31) for up to 14 days and none for >28 days. Eight (24%) had repeated courses. Ninety-one percent (n = 30) either avoided admission or were discharged early with resolution of infection. Four out of 33 patients had reversible blood abnormalities. The total cost for linezolid over this period was £58 000. However, 420 bed days, costing £500/day, were avoided, producing a total saving of £210 000 on inpatient costs.


Linezolid guidelines reduced lengths of stay, inpatient costs and overuse of this expensive but effective treatment.

Keywords: antibiotics; foot ulceration; MRSA; outpatient therapy

Journal Article.  1200 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.